- Home
- AARD vs KZIA Comparison
AARD vs KZIA Comparison
Compare AARD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | KZIA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 186.7M |
| IPO Year | 2025 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AARD | KZIA |
|---|---|---|
| Price | $5.56 | $10.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $15.29 | ★ $19.50 |
| AVG Volume (30 Days) | 125.5K | ★ 329.1K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $4.86 |
| 52 Week High | $17.94 | $17.40 |
Technical Indicators
Market Signals| Indicator | AARD | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 40.08 |
| Support Level | $5.47 | $10.59 |
| Resistance Level | $6.01 | $14.85 |
| Average True Range (ATR) | 0.55 | 0.82 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 59.53 | 14.69 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.